Valuation: Atara Biotherapeutics, Inc.

Market Cap 80.4M 72.01M 66.24M 60.02M 112M 7.63B 114M 790M 317M 4.02B 302M 295M 12.66B P/E 2026 *
-8.09x
P/E 2027 * 6.75x
Enterprise Value 80.4M 72.01M 66.24M 60.02M 112M 7.63B 114M 790M 317M 4.02B 302M 295M 12.66B EV / Sales 2026 *
28.2x
EV / Sales 2027 * 1.97x
Free-Float
83.2%
Yield 2026 *
-
Yield 2027 * -
1 day-6.10%
1 week-6.75%
1 month-5.76%
3 months-4.42%
6 months+67.92%
Current year-55.72%
1 week 7.72
Extreme 7.7231
8.84
1 month 7.72
Extreme 7.7231
9.99
Current year 3.92
Extreme 3.92
19.14
1 year 3.92
Extreme 3.92
19.14
3 years 3.92
Extreme 3.92
39.5
5 years 3.92
Extreme 3.92
501
10 years 3.92
Extreme 3.92
1,361.25
Manager TitleAgeSince
Chief Executive Officer 53 09/09/2024
Director of Finance/CFO 61 26/06/2026
Investor Relations Contact - 01/07/2023
Director TitleAgeSince
Director/Board Member 62 01/03/2014
Director/Board Member 66 23/11/2015
Director/Board Member 53 09/09/2024
Date Insider Type Main position Quantity % Market Cap. Importance
9/4/26 A Buy

Director

104,166 1.0377%
8/17/26 A Sell

Chief Executive Officer

-5,062 0.0562%
7/22/26 A
Redmile Group LLC
ExerciceCompany 390,482 4.3338%
Change 5-day change 1-year change 3-year change Capi.($)
-6.10%-6.75%-46.06%-75.16% 80.4M
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average -0.31%+6.11%+38.21%+167.97% 39.44B
Weighted average by Cap. +0.18%+5.44%+47.97%+176.62%

Financials

2026 *2027 *
Net sales 2.85M 2.55M 2.35M 2.13M 3.97M 270M 4.05M 27.99M 11.23M 142M 10.69M 10.46M 449M 40.87M 36.6M 33.67M 30.5M 57.02M 3.88B 58.09M 401M 161M 2.04B 153M 150M 6.44B
Net income -14.62M -13.09M -12.04M -10.91M -20.4M -1.39B -20.78M -144M -57.66M -730M -54.87M -53.7M -2.3B 18.66M 16.71M 15.37M 13.93M 26.03M 1.77B 26.52M 183M 73.57M 932M 70.01M 68.52M 2.94B
Net Debt - -
Projected Income Statement - Annual - Atara Biotherapeutics, Inc.
Logo Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
Employees
10
Date Price Change Volume
30/10/26 $8.010 -6.10% 29,961
29/10/26 $8.530 -1.50% 11,873
28/10/26 $8.660 +4.34% 26,854
27/10/26 $8.300 -0.60% 21,699
26/10/26 $8.350 -2.79% 35,268
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - Atara Biotherapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.010USD
Average target price
13.67USD
Spread / Average Target
+70.62%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Atara Biotherapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ATRA Stock